• By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
In the last 7 days
“You have to be a champion of failure” University of Zurich (Press Release)05:50 21-Jun-24
Roche launches B-cell lymphoma diagnostic assay in Europe Verdict Medical Devices04:21 21-Jun-24
Cipla to invest additional EUR 3 million in Ethris GmbH The Business Standard08:23 18-Jun-24
In the last month
Wacker steps up mRNA capacity in Germany Chemical & Engineering News18:49 13-Jun-24
COVID-19 vaccine “skeptics” are just antivax now Respectful Insolence10:23 10-Jun-24
Moderna’s mRNA vaccine approved for RSV Chemistry World Magazine07:32 7-Jun-24
FDA Green-Lights Moderna Vaccine for Older Adults Newswise (Press Release)08:52 6-Jun-24
Cartesian Therapeutics Announces New Employment Inducement Grant GlobeNewswire (Press Release)07:13 6-Jun-24
Data needed to forge the link between AI and mRNA Pharmaceutical Technology06:46 6-Jun-24
Exploring the Potential of mRNA (BIO 2024) PharmTech.com13:11 4-Jun-24
WACKER Opens a New Center for RNA Competence Genetic Engineering and Biotechnology News12:28 4-Jun-24
FDA approves Moderna’s mRNA vaccine for RSV in older adults McKnight's Long-Term Care News16:37 3-Jun-24
FDA approves Moderna’s RSV vaccine mRESVIA Pharmaceutical Technology04:42 3-Jun-24
view more headlines
21 Jun 14:30

About our mRNA news

Latest news on mRNA (messenger RNA), covering vaccines, therapeutics, research breakthroughs, clinical trials, and biotech companies like Moderna and BioNTech.

Messenger RNA, or mRNA, has revolutionized the fields of vaccine development and medical therapeutics. The technology gained global attention during the COVID-19 pandemic, with the rapid development and deployment of highly effective mRNA-based vaccines from Pfizer-BioNTech and Moderna. As of April 2024, billions of doses of these vaccines have been administered worldwide, significantly reducing the severity and mortality of COVID-19.

Beyond COVID-19, mRNA technology shows immense promise for treating various diseases, including cancer, genetic disorders, and infectious diseases. Ongoing clinical trials are investigating mRNA-based therapies for conditions such as HIV, influenza, and Zika virus. Additionally, researchers are exploring the potential of personalized mRNA cancer vaccines, which could revolutionize cancer treatment by targeting individual patients' unique tumor profiles.

The success of mRNA vaccines has sparked increased interest and investment in the biotech companies leading this innovation. Moderna and BioNTech have seen significant growth and partnerships with major pharmaceutical companies. The technology's versatility has also attracted the attention of philanthropic organizations, such as the Bill and Melinda Gates Foundation, which are funding research to address global health challenges.

The rapid development and success of mRNA vaccines during the COVID-19 pandemic built upon decades of foundational research. Scientists' understanding of mRNA's role in protein synthesis, combined with advancements in lipid nanoparticle delivery systems, paved the way for this breakthrough. The pandemic accelerated the translation of this research into life-saving interventions, demonstrating the importance of sustained investment in basic science.

As mRNA technology continues to advance, it is crucial to stay informed about the latest developments, clinical trial results, and regulatory approvals. Our NewsNow feed on mRNA provides comprehensive, up-to-date coverage from trusted sources, ensuring you have access to the most relevant information on this groundbreaking field and its impact on global health.

Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.